SLS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States...

Stats
Объем за сегодня	1.28M
Средний объем	1.47M
Рыночная капитализация	82.15M
EPS	$0 ( 2024-03-28 )
Дата следующего отчета о доходах	( $-0.210 ) 2024-05-09
Last Dividend	$0.420 ( 2010-12-09 )
Next Dividend	$0 ( N/A )
P/E	-1.090
ATR14	$0.00700 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Stergiou Angelos M.	Buy	159 000	Common Stock
2024-01-22	Stergiou Angelos M.	Buy	238 500	Stock Option (Right to Buy)
2024-01-22	Scheinberg David A	Buy	6 000	Common Stock
2024-01-22	Scheinberg David A	Buy	10 000	Stock Option (Right to Buy)
2024-01-22	Wood Barbara A	Buy	35 000	Common Stock

INSIDER POWER
95.64
Last 98 transactions
Buy: 3 194 450 \| Sell: 76 679

Объем Корреляция

Длинно: -0.14 (neutral)

Кратко: 0.62 (weak)

Signal:(56.941) Neutral

Sellas Life Sciences Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Sellas Life Sciences Корреляция - Валюта/Сырье

0.13
( neutral )

-0.40
( neutral )

0.00
( neutral )

0.49
( neutral )

0.00
( neutral )

0.30
( neutral )

Sellas Life Sciences Финансовые показатели

Annual	2023
Выручка:	$0
Валовая прибыль:	$0 (0.00 %)
EPS:	$-1.340

FY	2023
Выручка:	$0
Валовая прибыль:	$0 (0.00 %)
EPS:	$-1.340

FY	2022
Выручка:	$1.00M
Валовая прибыль:	$900 000 (90.00 %)
EPS:	$-2.10

FY	2021
Выручка:	$0.00
Валовая прибыль:	$-200 000 (0.00 %)
EPS:	$-2.60

Financial Reports:

No articles found.

Sellas Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sellas Life Sciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.150	2010-09-09
Last Dividend	$0.420	2010-12-09
Next Dividend	$0	N/A
Payout Date	2010-12-20
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.570	--
Avg. Dividend % Per Year	0.00%	--
Score	1.52	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-08)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.52

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2010	$0.570	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-5.80	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-23.94	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.231	0.800	-3.85	-3.08	[1 - 3]
quickRatioTTM	0.191	0.800	-3.58	-2.86	[0.8 - 2.5]
cashRatioTTM	0.191	1.500	-0.0473	-0.0710	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	154.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
freeCashFlowPerShareTTM	-1.242	2.00	-0.621	-1.242	[0 - 20]
debtEquityRatioTTM	-0.114	-1.500	-0.454	0.682	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-34.67	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.91

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.262	1.000	-0.229	0	[1 - 100]
returnOnEquityTTM	-23.94	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.242	2.00	-0.414	-1.242	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0245	1.500	-3.50	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.945

Sellas Life Sciences

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.